{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:36:27Z","timestamp":1792877787501,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02385-z","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:39:09Z","timestamp":1790303949000},"page":"1953-1959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Camizestrant: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2385_CR1","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.2147\/DDDT.S380925","volume":"16","author":"T Downton","year":"2022","unstructured":"Downton T, Zhou F, Segara D, et al. Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status. Drug Des Devel Ther. 2022;16:2933\u201348.","journal-title":"Drug Des Devel Ther."},{"key":"2385_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.05.707","author":"E de Azambuja","year":"2026","unstructured":"de Azambuja E, Barrios CH, Bartsch R, et al. Metastatic breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.05.707.","journal-title":"Ann Oncol"},{"key":"2385_CR3","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 4.2026, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2026;24(7)."},{"key":"2385_CR4","doi-asserted-by":"publisher","first-page":"11579","DOI":"10.1038\/ncomms11579","volume":"7","author":"JM Spoerke","year":"2016","unstructured":"Spoerke JM, Gendreau S, Walter K, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579.","journal-title":"Nat Commun"},{"key":"2385_CR5","unstructured":"AstraZeneca. Camizestrant in combination with a CDK4\/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer [media release]. 22 May 2026. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2026\/camizestrant-recommended-for-breast-cancer-in-eu.html."},{"issue":"23","key":"2385_CR6","doi-asserted-by":"publisher","first-page":"14530","DOI":"10.1021\/acs.jmedchem.0c01163","volume":"63","author":"JS Scott","year":"2020","unstructured":"Scott JS, Moss TA, Balazs A, et al. Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist. J Med Chem. 2020;63(23):14530\u201359.","journal-title":"J Med Chem"},{"issue":"23","key":"2385_CR7","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","volume":"83","author":"M Lawson","year":"2023","unstructured":"Lawson M, Cureton N, Ros S, et al. The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance. Cancer Res. 2023;83(23):3989\u20134004.","journal-title":"Cancer Res"},{"key":"2385_CR8","unstructured":"The Saudi Press Agency (SPA). SFDA approves registration of new treatment for advanced or metastatic breast cancer with a gene mutation [media release]. 15 May 2026. https:\/\/www.spa.gov.sa\/en\/N2586464."},{"key":"2385_CR9","unstructured":"Emirates Drug Establishment. Registered medical product directory. 2025. https:\/\/www.ede.gov.ae\/en\/drug-directory. Accessed 31 Aug 2026."},{"key":"2385_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s10147-026-03119-7","volume":"31","author":"PMDA Regulatory Update","year":"2026","unstructured":"PMDA Regulatory Update. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer. Int J Clin Oncol. 2026;31:1419\u201321.","journal-title":"Int J Clin Oncol"},{"key":"2385_CR11","unstructured":"AstraZeneca. Etcamah (camizestrant) in combination with a CDK4\/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer [media release]. 23 Jul 2026. https:\/\/news.cision.com."},{"key":"2385_CR12","unstructured":"The Institute of Cancer Research. ICR welcomes MHRA approval of breast cancer drug that targets tumours before they have a chance to grow [media release]. 7 Aug 2026. https:\/\/www.icr.ac.uk\/about-us\/icr-news\/detail\/icr-welcomes-mhra-approval-of-breast-cancer-drug-that-targets-tumours-before-they-have-a-chance-to-grow."},{"key":"2385_CR13","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval to a new breast cancer treatment [media release]. 4 Sep 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-new-breast-cancer-treatment."},{"key":"2385_CR14","unstructured":"European Medicines Agency. Etcamah (camizestrant) 75 mg film-coated tablets: EU summary of product characteristics. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/etcamah-epar-product-information_en.pdf. Accessed 31 Aug 2026."},{"issue":"9","key":"2385_CR15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1200\/JCO-25-01548","volume":"44","author":"JFR Robertson","year":"2026","unstructured":"Robertson JFR, Gogitidze T, Katashvili Z, et al. Pharmacodynamics of camizestrant treatment in postmenopausal women with estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative primary breast cancer: results from the randomized, presurgical SERENA-3 study. J Clin Oncol. 2026;44(9):750\u201361.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2385_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S1470-2045(26)00287-1","volume":"27","author":"NC Turner","year":"2026","unstructured":"Turner NC, Mayer EL, Park YH, et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026;27(8):941\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2385_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.annonc.2025.10.006","volume":"37","author":"EL Mayer","year":"2026","unstructured":"Mayer EL, Bidard FC, Park YH, et al. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4\/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. Ann Oncol. 2026;37(2):180\u201393.","journal-title":"Ann Oncol"},{"issue":"20","key":"2385_CR18","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1158\/1078-0432.CCR-25-1198","volume":"31","author":"RD Baird","year":"2025","unstructured":"Baird RD, de Las Heras BB, Ruiz-Borrego M, et al. Camizestrant in combination with three globally approved CDK4\/6 inhibitors in women with ER+, HER2- advanced breast cancer: results from SERENA-1. Clin Cancer Res. 2025;31(20):4244\u201354.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2385_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.esmoop.2025.106049","volume":"11","author":"C Vaklavas","year":"2026","unstructured":"Vaklavas C, Oliveira M, Armstrong AC, et al. Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1. ESMO Open. 2026;11(2):1\u201311.","journal-title":"ESMO Open"},{"issue":"8","key":"2385_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","volume":"35","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Oliveira M, Turner N, et al. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024;35(8):707\u201317.","journal-title":"Ann Oncol"},{"issue":"4","key":"2385_CR21","doi-asserted-by":"publisher","first-page":"PS1-10-28","DOI":"10.1158\/1557-3265.SABCS25-PS1-10-28","volume":"32","author":"TA Yap","year":"2026","unstructured":"Yap TA, Yonemori K, Li W, et al. Phase 1\/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced\/relapsed ER+\/HER2-negative or low (HER2\u2212) breast cancer (PETRA Module 6) [abstract no. PS1-10-28]. Clin Cancer Res. 2026;32(4):PS1-10\u201328.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2385_CR22","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","volume":"25","author":"M Oliveira","year":"2024","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024;25(11):1424\u201339.","journal-title":"Lancet Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02385-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:02:12Z","timestamp":1792875732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2385"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02385-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}